Human Kallikrein 8, His Tag (KL8-H5229) is expressed from human 293 cells (HEK293). It contains AA Gln 29 - Gly 260 (Accession # AAH40887).
Predicted N-terminus: Gln 29
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 25.8 kDa. The protein migrates as 38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Pre-activation is required for enzymatic assays. Please dilute Human Kallikrein 8 to 200 µg/mL in activation buffer (50 mM Tris, pH 8.0), and then dilute Lysyl-Endopeptidase to a final concentration of 0.4 mU/mL in activation buffer. Combine equal volume of diluted KLK8 and Lysyl-Endopeptidase together and incubate at 37 ℃ for 30 minutes. Please note that the optimal treatment time may need to be determined empirically.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH 8.0. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human Kallikrein 8, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Kallikrein-8 (KLK8) is also known as Neuropsin (NP or NRPN), Ovasin, Serine protease 19 (PRSS19), Tumor-associated differentially expressed gene 14 protein (TADG-14), which belongs to the peptidase S1 family and Kallikrein subfamily. KLK8 contains 1 peptidase S1 domain. KLK8 is pH dependence protein and the optimum pH is 8.5, and the protein is active from pH 7-10. KLK8 is expressed at high levels in serum, ascites fluid and tumor cytosol of advanced stage ovarian cancer patients and may serve as a marker of ovarian cancer. KLK8 cleavage of amide substrates following the basic amino acids Arg or Lys at the P1 position, with a preference for Arg over Lys, and the catalytic activity of KLK8 is inhibited by a range of serine protease inhibitors including antipain, aprotinin, leupeptin, benzamidine and soybean trypsin inhibitor.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.